NASDAQ$RNA

Atrium Therapeutics Inc · Q1 2023 earnings

Q1 2023 earnings ·

Headline financials

Total Revenue

$2.23M

Previous: $1.8M+24.4%
EPS

-$0.74

No prior period
Capital Expenditures

-$1.82M

Previous: -$758K-140.1%
Free Cash Flow

-$54.2M

Previous: -$35M-54.9%
Net Income

-$52.4M

Previous: -$34.2M-53.0%
Operating Income

-$57.6M

Previous: -$34.5M-67.1%
Gross Profit

$0.00

Previous: $0.00

Revenue & EPS history

Atrium Therapeutics Inc · Revenue · Quarterly

$2.23M

Q1 2023+24.4%vs Q1 2022
Beat estimate in 1 of 1 quarters(100%)
ActualEstimate

Revenue by segment

Atrium Therapeutics Inc · $19.6M total across 1 segment · Q1 2026

  • Reportable Segment
    $19.6M—

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro